For the quarter ending 2025-09-30, KRRO had -$9,457K decrease in cash & cash equivalents over the period. -$17,354K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -18,061 | -49,157 |
| Non-cash lease expense | 178 | 326 |
| Stock-based compensation expense | 1,825 | 3,759 |
| Depreciation expense | 1,179 | 2,452 |
| Net amortization of premiums and discounts on marketable securities | 467 | - |
| Loss on disposal of property and equipment | -81 | - |
| Accounts receivable | -876 | - |
| Prepaid expenses and other current assets | 189 | - |
| Accounts payable | -1,674 | - |
| Accrued expenses and other current liabilities | -319 | - |
| Deferred revenue | -1,268 | - |
| Operating lease liabilities | -97 | - |
| Other non-current assets | 303 | - |
| Net cash used in operating activities | -17,179 | -43,680 |
| Purchases of marketable securities | 15,028 | 11,161 |
| Proceeds from maturities of marketable securities | 22,799 | 32,901 |
| Purchases of property and equipment | 175 | 259 |
| Net cash provided by (used in) investing activities | 7,596 | 21,481 |
| Proceeds from pipe financing, net of issuance costs | 0 | 0 |
| Proceeds from exercises of stock options | 128 | 177 |
| Net cash provided by financing activities | 128 | 177 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -2 | -9 |
| Net decrease in cash, cash equivalents and restricted cash | -9,457 | -22,031 |
| Cash and cash equivalents at beginning of period | 59,049 | - |
| Cash and cash equivalents at end of period | 27,561 | - |
Korro Bio, Inc. (KRRO)
Korro Bio, Inc. (KRRO)